Zhitong Financial App News, Maiwei Bio-B (02493.HK) announced that the company will announce the phase II clinical study data of targeted Nectin-4 ADC innovative drugs for patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who have previously received ADC treatment with topoisomerase I inhibitors at the 2026 European Society of Medical Oncology (ESMO) conference to be held in Madrid, Spain from October 23 to October 27, 2026:

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.